The flurry of deals comes as Roche is facing biosimilar competition for its ‘big three’ antibodies – Rituxan, Herceptin and ... meaning they have no known function but could turn out to ...

Dr Rebecca Dobson discussed the acute need to assess cardiovascular risk in cancer care, cardiotoxicity and the MDT in cardio ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

Despite the impact of the pandemic on cancer care, Perjeta grew 17% to CHF 2.9 billion ($3.2 billion) in the first nine months of 2020, now just fractionally behind Herceptin which declined 31% to ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

(3) Intracellular alterations. In trastuzumab resistant cells, PTEN function is lost; thus, Akt is constitutively active. Also, resistant cells can harbor activating mutations in PI3K or Akt, which ...